2F-2oxo-PCE (CanKet): Complete Toxicology, FXE Isomer Confusion & Safety Monograph

2F-2oxo-PCE (CanKet): Complete Toxicology, FXE Isomer Confusion & Safety Monograph

Emergency dissociative/unknown-drug warning: Severe unresponsiveness, abnormal breathing, blue or gray color, seizure, repeated vomiting with reduced consciousness, collapse, dangerous agitation/confusion, or serious injury after an unknown dissociative requires urgent medical care. If an opioid may also be present and breathing is slow or absent, give naloxone if available while emergency help is activated.

Quick answer

2F-2oxo-PCE is a fluorinated arylcyclohexylamine dissociative commonly called CanKet. It is the 2-fluoro positional isomer of fluorexetamine, which is properly 3F-2oxo-PCE.

That positional-isomer distinction is the central analytical issue.

For several years, some material and biological specimens were reported as “fluorexetamine/FXE” using methods that could identify the molecular formula but could not prove which ring position carried fluorine.

Once reference standards and chromatographic separation improved, North American investigators found that much of the material was actually 2F-2oxo-PCE.

The compound now has a meaningful human forensic evidence base, but controlled clinical pharmacology remains sparse.

Identity

History and emergence

The compound was first brought to broad analytical attention in early 2022 by Australia's CanTEST drug-checking service, which used the informal name CanKet.

North American casework followed soon afterward.

CFSRE received an early toxicology case in late 2022 that was initially characterized as fluorexetamine-like.

At that time, its LC-QTOF-MS workflow could identify the molecular formula and general structure but could not resolve the fluorine position.

Later access to positional-isomer reference standards changed the interpretation.

By May 2024, CFSRE reported:

• more than 20 drug materials;
• 35 toxicology specimens;
• detections across at least nine U.S. states or Canadian provinces.

That is a rapid transition from obscure RC to geographically distributed forensic substance.

CanKet vs FXE

This distinction should be explicit everywhere.

2F-2oxo-PCE

• fluorine at the 2-position;
• commonly called CanKet.

FXE / fluorexetamine

• fluorine at the 3-position;
• properly 3F-2oxo-PCE.

Both share the same molecular formula.

That means:

• exact mass alone is insufficient;
• some fragmentation patterns are extremely similar;
• an older library match can assign the wrong isomer.

Why older “FXE” case reports need caution

Early forensic work sometimes reported “FXE” when the available method could not distinguish:

• 2F-2oxo-PCE;
• 3F-2oxo-PCE.

When later reference standards became available, CFSRE and other laboratories repeatedly identified 2F-2oxo-PCE in North American casework.

Therefore an old “FXE” result should be interpreted according to:

• chromatography;
• retention time;
• reference standard;
• whether positional isomers were actually resolved.

The name in the report is not automatically molecular proof.

Pharmacology

Direct receptor-level pharmacology for 2F-2oxo-PCE remains much thinner than for ketamine or classic PCP analogues.

Its arylcyclohexylamine structure and observed dissociative market profile strongly support NMDA-receptor antagonist activity.

That is a class-supported mechanism, not a completed controlled pharmacology program.

What is not established

There is no reliable human:

• ketamine-equivalence ratio;
• FXE-equivalence ratio;
• receptor occupancy curve;
• therapeutic index.

Human toxicology surveillance

CFSRE's North American data demonstrate real human exposure.

By May 2024, 35 toxicology specimens had been identified.

The samples came from multiple jurisdictions and reflected a dynamic drug supply.

Many specimens involved other drugs, which limits clean attribution of symptoms or cause of death.

Postmortem evidence from South Korea

A 2026 Korean autopsy study provided one of the strongest human analytical datasets for 2F-2oxo-PCE.

Postmortem blood concentrations ranged from approximately:

• 664 to 7,911 ng/mL.

The study also identified 2F-deschloronorketamine (2F-DCNK) as a metabolite.

Concurrent substances included:

• MDMA;
• ketamine.

What the autopsy concentrations mean

They establish:

• human exposure;
• measurable postmortem distribution;
• relevance in fatal investigations.

They do not establish:

• a lethal threshold;
• a safe concentration below that range;
• 2F-2oxo-PCE as the sole cause of death in every case.

Polydrug exposure matters.

2F-DCNK as a metabolite

The Korean study identified 2F-deschloronorketamine after 2F-2oxo-PCE exposure.

That metabolite can strengthen exposure confirmation when parent drug is:

• low;
• declining;
• absent in a particular specimen.

Interpretation problem

2F-DCNK is also analytically relevant to other fluorinated ketamine analogues.

A metabolite should therefore be interpreted in context with:

• parent compounds;
• chromatographic identity;
• specimen type;
• other ketamine analogues.

Human hair evidence

A 2026 Forensic Science International study developed and validated an LC-MS/MS method for simultaneous detection of:

• 2F-2oxo-PCPr;
• 2F-2oxo-PCE;
• 2F-DCK;
• ketamine;
• related metabolites.

The method was applied to hair from eight people.

Hair evidence is useful for establishing prior exposure over a broader time window than blood.

It does not establish:

• acute impairment;
• exact time of use;
• dose.

North American product evidence

CFSRE reported that more than 60% of tested 2F-2oxo-PCE drug materials contained opioids, most often fentanyl.

Other associated substances included:

• xylazine;
• designer benzodiazepines;
• nitazenes;
• stimulants.

This makes real-world CanKet exposure qualitatively different from a hypothetical pure laboratory compound.

Opioid co-exposure risk

A dissociative does not protect against opioid respiratory depression.

If 2F-2oxo-PCE is present with fentanyl or another opioid, possible danger includes:

• profound unconsciousness;
• respiratory arrest;
• aspiration;
• hypoxia;
• death.

Naloxone can reverse the opioid component.

It does not reverse NMDA-antagonist dissociation.

Product labels are unreliable

2F-2oxo-PCE has appeared in products or case contexts described as:

• “fluorexetamine”;
• “FXE”;
• “dope”;
• “K2”/synthetic-cannabinoid-type material;
• mixed illicit powders.

This is a cross-class identity problem.

The user's expected drug class may be wrong before intoxication even begins.

Correctional-facility drug papers

Analytical studies of drug-infused papers seized in correctional settings have detected 2F-2oxo-PCE alongside combinations of:

• synthetic cannabinoids;
• nitazenes;
• fentanyl;
• xylazine;
• methamphetamine;
• other NPS.

That demonstrates another exposure format outside powders or crystals.

Acute toxicity

Clean isolated clinical case series remain limited.

Based on arylcyclohexylamine pharmacology and human casework, plausible/observed concerns include:

• dissociation;
• confusion;
• agitation;
• nystagmus;
• impaired coordination;
• reduced consciousness;
• vomiting;
• hypertension/tachycardia;
• accidental trauma.

Severe mixed exposures can add:

• respiratory depression from opioids/sedatives;
• seizure;
• aspiration;
• cardiovascular instability.

Behavioral and trauma risk

Dissociatives can impair:

• perception;
• judgment;
• balance;
• response to danger.

Serious harm can therefore occur indirectly through:

• falls;
• traffic incidents;
• drowning;
• unsafe wandering;
• risky behavior while dissociated.

A drug does not need to be the direct physiologic cause of death to contribute materially to the circumstances.

Interactions

No controlled 2F-2oxo-PCE interaction studies establish safe combinations.

High-concern combinations include:

• opioids → respiratory depression;
• alcohol/benzodiazepines → deeper unconsciousness and aspiration risk;
• other dissociatives → unpredictable depth/duration;
• stimulants → greater cardiovascular/behavioral stress.

Because mixed products are common, unintended interaction is part of the real-world risk.

Metabolism

Direct human evidence now supports conversion to 2F-DCNK.

Additional metabolism is likely to include ketamine-analogue oxidative pathways, but a complete controlled human metabolite map remains incomplete.

This article does not simply copy 2F-DCK or ketamine metabolism onto CanKet.

Pharmacokinetics

No controlled human study establishes a universal:

• bioavailability;
• time to peak;
• terminal half-life;
• clearance;
• repeated-use accumulation;
• concentration-effect curve.

Autopsy blood concentrations are not pharmacokinetic studies.

Community duration reports are not substitutes for measured PK.

Drug testing

Routine immunoassays

Routine workplace/emergency panels should not be expected to identify 2F-2oxo-PCE specifically.

A ketamine screen may also fail to answer which fluorinated analogue is present.

Definitive methods

Useful methods include:

• LC-MS/MS;
• LC-QTOF-MS;
• LC-HRMS;
• parent + metabolite targets;
• chromatographic separation against authentic positional-isomer standards.

The isomer-resolution rule

A laboratory report should not confidently call a specimen “FXE” or “2F-2oxo-PCE” unless the analytical method can actually distinguish the positional isomers.

Useful evidence includes:

• retention-time separation;
• reference standards;
• validated transition/fragment patterns;
• orthogonal confirmation when needed.

This is one of the most important forensic lessons on the page.

Tolerance

Repeated NMDA-antagonist exposure can produce tolerance to dissociative effects.

There are no controlled human 2F-2oxo-PCE tolerance studies.

Subjective tolerance does not guarantee protection from:

• impaired coordination;
• accidents;
• unconsciousness;
• urinary/cognitive toxicity;
• mixed-drug overdose.

Dependence and problematic use

2F-2oxo-PCE-specific dependence epidemiology does not exist.

Ketamine and other dissociatives can support compulsive repeated use.

A reasonable evidence statement is:

Repeated CanKet use can plausibly become problematic through NMDA-antagonist class mechanisms, but the incidence and severity of 2F-2oxo-PCE dependence are not established.

Withdrawal

No validated 2F-2oxo-PCE withdrawal syndrome or timeline exists.

Frequent dissociative users can experience:

• craving;
• low mood;
• anxiety;
• irritability;
• sleep disturbance;
• difficulty stopping.

Those are class-level/repeated-use concerns, not a proven CanKet withdrawal clock.

Treatment and support

There is no medication approved specifically for 2F-2oxo-PCE use disorder.

Acute management is supportive and complication-directed, including attention to:

• airway;
• consciousness;
• trauma;
• cardiovascular state;
• co-drugs.

Problematic repeated use can be addressed through substance-use and mental-health care.

U.S. resources include:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Bladder and urinary toxicity

Chronic heavy ketamine use can cause severe urinary-tract injury.

Direct CanKet cystitis incidence is unknown.

Because 2F-2oxo-PCE is a ketamine-related arylcyclohexylamine, urinary toxicity is a class-level concern, not a quantified molecule-specific risk.

Persistent urinary pain, urgency, frequency or blood in urine warrants medical evaluation.

Cognitive and psychiatric effects

Long-term human 2F-2oxo-PCE data are absent.

Class concerns include:

• memory/cognitive impairment with heavy repeated dissociative use;
• psychiatric destabilization;
• functional impairment;
• persistent risky use.

These should remain clearly labeled as extrapolation from related dissociatives.

Forensic interpretation

Detection does not prove sole causation

Polydrug exposure is common in CanKet casework.

Blood concentration does not equal dose

The Korean autopsy range is not a lethal-dose chart.

Measured concentration depends on:

• timing;
• metabolism;
• tolerance;
• specimen;
• postmortem change;
• co-drugs.

Hair establishes exposure history, not acute impairment

A positive hair result supports prior exposure but does not prove intoxication at a specific event.

Isomer certainty is foundational

A concentration from a historical “FXE” case should not be reused as a CanKet reference unless the method actually separated the isomers.

Special populations

No adequate controlled 2F-2oxo-PCE safety data exist for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• urinary disease;
• severe psychiatric illness;
• liver/kidney impairment.

Missing evidence is not evidence of safety.

Legal status — dated October 3, 2026

United States

CFSRE described 2F-2oxo-PCE as not federally scheduled in its 2024 public-health alert.

Subsequent 2025 clinical-surveillance summaries likewise described it as not specifically federally scheduled.

This review did not identify a later primary federal scheduling action specifically naming 2F-2oxo-PCE by October 3, 2026.

That does not establish that every possession or distribution scenario is lawful.

Possible legal exposure includes:

• state-specific scheduling;
• federal analogue-law analysis depending on facts;
• other controlled-substance statutes.

International

International control varies by jurisdiction.

This review does not identify a UN convention scheduling decision specifically naming 2F-2oxo-PCE as of October 3, 2026.

Myths and misconceptions

“CanKet and FXE are the same drug.”
False. They are positional isomers.

“Every old FXE toxicology result is definitely 3F-FXE.”
False. Some methods could not resolve fluorine position.

“A 7,000-ng/mL autopsy result means that concentration is fatal.”
False. Autopsy concentrations are case observations, not thresholds.

“A negative ketamine screen rules out CanKet.”
False.

“If a product is sold as FXE, it probably contains a pure dissociative.”
False. North American samples frequently contained opioids and other high-risk drugs.

“Ketamine bladder toxicity proves CanKet causes cystitis at the same rate.”
No. It creates a class-level concern, not a known incidence.

Evidence ledger

Related evidence

• FXE / Fluorexetamine
• 2F-DCK
• DCK
• O-PCE
• DMXE
• 3-MeO-PCE
• RC dissociatives evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

2F-2oxo-PCE/CanKet is one of the clearest examples of why modern NPS toxicology needs isomer-level identification.

The substance has spread widely enough to appear in dozens of North American toxicology cases, Korean autopsies, human hair, mixed drug materials, and correctional-facility papers.

But older “FXE” data cannot simply be copied onto it.

The highest-value safety message is:

Prove the isomer, account for the opioids and other co-drugs, and never turn an autopsy concentration into a personal safety threshold.